ASH_hematology VTE Guidelines In Patients With Cancer

12 Mar, 2021

Dr. Rajesh Bollam

Image

1/ New @ASH_hematology VTE guidelines in patients with cancer:

Summary below,⭐️= Strong recommendation (only 2/34)

2/ Hospitalized medical patients with cancer WITHOUT VTE:

🩸Ppx>no ppx

🩸Pharmacologic>mechanical

🩸Pharmacologic > mechanical+pharmacologic

🩸LMWH>UFH

🩸Stop thromboppx at discharge

3/ Patients with cancer WITHOUT VTE with surgery:

🩸Low bleeding risk: pharm>mech

🩸High bleeding risk: mech>pharm

🩸High thrombosis + low bleeding risk: mech+pharm>either alone

🩸LMWH or fondaparinux>UFH

🩸No VKA or DOAC for ppx

🩸Major abd/pelvic surgery: cont pharm post dc

4/ Ambulatory patients with cancer on systemic therapy:

⭐️Low thrombosis risk: no parenteral ppx

🩸Int thrombosis risk: no parenteral ppx

🩸Low thrombosis risk: no ppx>VKA or DOAC

🩸Int thrombosis risk: DOAC>no ppx

🩸High thrombosis risk: LMWH>no ppx, DOAC>no ppx

5/ Ambulatory patients with cancer on systemic therapy (cont):

🩸No ppx>VKA

🩸For patients with multiple myeloma on lenalidomide/thalidomide/pomalidomide, use low-dose ASA + fixed-dose VKA or LMWH

Patients with cancer and a CVC:

🩸No oral ppx

6/ Initial rx in first week for patients with active cancer + VTE:

🩸Use DOAC or LMWH

⭐️LMWH>UFH

🩸 LMWH>fondaparinux

7/ Short-term (3-6 months) rx for active cancer + VTE:

🩸DOAC>LMWH or VKA

🩸LMWH>VKA

🩸Incidental or subsegmental PE or visceral/splanchnic vein thrombosis: short-term anticoagulation > observation

🩸CVC-related VTE: keep CVC

🩸Recurrent VTE on LMWH: ⬆️LMWH dose, no IVC filter

8/ Long-term (>6 months) rx for active cancer + VTE:

🩸>6 months anticoagulation > 3-6 months alone

🩸Continue indefinite anticoagulation over stopping after a period

🩸Use DOAC or LMWH

#DrRajeshBollam #HematoOncologist #CancerSpecialist #cancerdoctor #VTE #anticoagulation #hyderabad #Secundrabad #telangana

Add a comment